offerwriter6

About

A new cycle 3 demo involving safety, tolerability, and also immunogenicity regarding V114, 15-valent pneumococcal conjugate vaccine, weighed against 13-valent pneumococcal conjugate vaccine in grown-ups 50 years old enough along with more mature (PNEU-AGE).